Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer.

Rita Nehmé; Marlène Fortier; Philippine Granger Joly de Boissel; France Caza; Fanny Fronton; Léa Bourguignon; Tania Charpentier; Camille Fuselier; Sophia Ferchiou; Noémie D'Auteuil; Louis Gaboury; Alain Lamarre; David Chatenet; Yves St-Pierre

doi:10.1021/acs.jmedchem.6c00142

April 29, 2026

Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer.

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to explore the therapeutic potential of minibodies targeting galectin-1 and galectin-7 in triple-negative breast cancer (TNBC).
Engineered minibodies were developed to block galectin-1 and galectin-7.
The study assessed their effects on immune functions and cancer progression in TNBC models.
Immunotherapy strategies leveraging these minibodies were evaluated for efficacy.
Selective blockade of galectin-1 and galectin-7 enhanced anti-tumor immune responses.
Therapeutic treatment led to significant tumor regression in TNBC models, showing a marked increase in T-cell activity.
Results indicate potential for expanded immunotherapy options targeting glyco-immune pathways.

Implication

Reveals glyco-immune functions of minibodies targeting galectins in triple-negative breast cancer, suggesting new immunotherapy options.

Abstract

Tregs. These findings demonstrate that selective GAL blockade with engineered minibodies is a promising strategy to expand immunotherapy options in TNBC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nehmé et al. (2026) studied this question.

synapsesocial.com/papers/69f5947e71405d493afff474 https://doi.org/10.1021/acs.jmedchem.6c00142

View Full Paper

Ask AI

Bookmark

Share

Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer.

Key Points

Implication

Abstract

Discussion

Cite This Study

Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading